超10亿美元！前沿生物牵手GSK，小核酸赛道再升温

Core Viewpoint - Frontier Biotech has entered into a significant exclusive licensing agreement with GlaxoSmithKline (GSK) for two small nucleic acid (siRNA) pipeline products, which is expected to enhance the company's cash flow and support its research and development efforts amid ongoing losses since its IPO in 2020 [1][8]. Company Summary - Frontier Biotech announced an exclusive licensing agreement with GSK on February 23, granting GSK global rights for the development, production, and commercialization of two siRNA products [1]. - The agreement includes an upfront payment of $40 million and a milestone payment of $13 million, with potential total payments reaching up to $950 million based on successful development and commercialization milestones [1]. - The company has been facing financial challenges, with a reported net loss of 260 million yuan in 2021, despite a 59.75% increase in sales volume of its core product, Aikening [6][8]. - Frontier Biotech's revenue primarily comes from Aikening and other products, with a projected revenue of 140 to 145 million yuan in 2025, indicating a year-on-year growth of 8.13% to 11.99% [8]. Industry Summary - The global small nucleic acid market is expected to grow significantly, projected to reach $39.2 billion by 2029, indicating a vast growth potential in this therapeutic area [8]. - As of December 2025, there are 29 small nucleic acid drugs on the market, with notable sales performance from Novartis's siRNA drug Leqvio, which reported sales of $1.198 billion in 2025, a 57% increase [9]. - The small nucleic acid sector is experiencing increased transaction activity, with potential total transaction values in the field expected to reach $36.5 billion by 2025 [9]. - Chinese pharmaceutical companies are actively engaging in international collaborations and mergers to enhance their presence in the small nucleic acid space, with significant partnerships and acquisitions reported [10][11]. - The industry is facing challenges, including a gap in the number of products developed by Chinese teams compared to global counterparts, particularly in late-stage clinical trials [12].